Changes of higher-order aberrations with the use of various mydriatics.
Advances in corneal refractive surgery have allowed ophthalmologists to correct ocular higher-order aberrations. To obtain more information on the ocular aberrations generated from the optical axis, mydriasis is required. The aim of this study is to evaluate the changes in higher-order aberrations with the use of various mydriatics. Higher-order aberrations were measured in 21 eyes of 21 subjects (age range 24-37 years; 13 males, 8 females). Repeated measurements were conducted before and after the installation of three different mydriatics: 10% phenylephrine, 1% tropicamide, or 1% cyclopentolate. At a pupil size of 6 mm, the average root mean square value of higher-order aberrations (HO-RMS) was 0.430 mum in undilated eyes, and 0.413, 0.410, and 0.477 mum after installation of phenylephrine, tropicamide, and cyclopentolate, respectively. There were no statistically significant differences in the HO-RMS between the four conditions. There was a significant difference in the spherical aberration between the undilated or phenylephrine-treated eyes, compared to those treated with tropicamide or cyclopentolate. Cycloplegic mydriatics seemed to shift spherical aberration in a positive direction. These results suggest that mydriatics may affect higher-order aberrations, especially spherical aberration, and this should be considered when performing wavefront analysis and when correcting wavefront errors.
Kim
Jae-Hyung
JH
Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul 138-736, Korea.
Lim
Taehyung
T
Kim
Myoung Joon
MJ
Tchah
Hungwon
H
D000287:Administration, Topical; D000328:Adult; D003315:Cornea / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D011680:Pupil / Q000187:drug effects* / Q000502:physiology; D012029:Refraction, Ocular / Q000187:drug effects* / Q000502:physiology; D012030:Refractive Errors / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects* / Q000502:physiology; D055815:Young Adult
D009184:Mydriatics; D009883:Ophthalmic Solutions